Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a new staging system better predict esophageal cancer outcomes?

NCT ID NCT07488624

Knowledge-focused Sponsor: Sichuan University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Aug 14, 2026 · Updated 3 times

Summary

This study analyzed data from 414 esophageal cancer patients who received chemoimmunotherapy before surgery. Researchers developed a new 'bio-anatomical' staging system that combines tumor characteristics and immune response to better predict survival and guide post-surgery treatment decisions. The goal is to improve upon traditional staging methods for personalized care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a more accurate tool for doctors to predict survival and choose the best follow-up treatment for esophageal cancer patients after chemoimmunotherapy and surgery.
What could go wrong
This is a retrospective observational study, not a clinical trial testing a new treatment. The model needs further validation in prospective studies before it can be used in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

414 people

The number who actually took part.

Started

Mar 2026

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population was drawn from patients with esophageal squamous cell carcinoma treated at West China Hospital, Sichuan University; Mianzhu People's Hospital (West China Mianzhu Hospital, Sichuan University); and Suining Central Hospital between 2019 and 2025. Patients received neoadjuvant chemoimmunotherapy followed by esophagectomy as part of routine clinical care.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Age 18 to 80 years Histologically confirmed esophageal squamous cell carcinoma Received at least 1 cycle of neoadjuvant chemoimmunotherapy before surgery Underwent subsequent esophagectomy Exclusion Criteria: History of other malignancies Preoperative antitumor therapy other than neoadjuvant chemoimmunotherapy Incomplete clinicopathologic or follow-up data

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESCC are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

esophageal squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESCC Esophageal squamous cell carcinoma

Contacts and locations

Locations

  • Mianzhu People's Hospital (West China Mianzhu Hospital, Sichuan University)

    Mianzhu, Sichuan, 618200, China

  • Suining Central Hospital

    Suining, Sichuan, 629000, China

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.